LHW 090

Drug Profile

LHW 090

Alternative Names: LHV-527; LHW090

Latest Information Update: 16 Jul 2016

Price : $50

At a glance

  • Originator Novartis
  • Class
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Resistant hypertension
  • No development reported Kidney disorders

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for phase-I development in Kidney-disorders in USA (PO, Capsule)
  • 15 Feb 2016 Novartis Pharmaceuticals plans a phase II trial for Chronic kidney disorders (Treatment-experienced, In adults, In the elderly) in USA, Germany and Romania (PO) (NCT02678000)
  • 01 Nov 2015 Phase-II clinical trials in Resistant hypertension in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top